Potential SARS-CoV-2 kidney infection and paths to injury

Luise Hassler; Daniel Batlle

doi:10.1038/s41581-022-00551-6

Potential SARS-CoV-2 kidney infection and paths to injury

Luise Hassler, Daniel Batlle^*

^*Corresponding author for this work

Medicine, Nephrology Division

Research output: Contribution to journal › Comment/debate › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	275-276
Number of pages	2
Journal	Nature Reviews Nephrology
Volume	18
Issue number	5
DOIs	https://doi.org/10.1038/s41581-022-00551-6
State	Published - May 2022

Funding

We acknowledge Jan Wysocki and Juan Carlos Velez for the careful reading of the manuscript and their suggestions before submission. We acknowledge the support of a gift from the Joseph and Bessie Feinberg Foundation, NIH grant 1R21 AI166940-01 (D.B.) and a stipend from the BMEP to L.H. D.B. is co-inventor of patents entitled “Active Low Molecular Weight Variants of Angiotensin Converting Enzyme 2 (ACE2)”, “Active low molecular weight variants of Angiotensin Converting Enzyme 2 (ACE2) for the treatment of diseases and conditions of the eye” and “Soluble ACE2 Variants and Uses therefor”; is founder of Angiotensin Therapeutics Inc.; has received consulting fees from AstraZeneca, Relypsa and Tricida (all unrelated to this work); and has received unrelated support from National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK104785, as well as from a grant from AstraZeneca. L.H. declares no competing interests.

ASJC Scopus subject areas

Nephrology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41581-022-00551-6

Cite this

@article{40f64437de7d41d2af68a08d7fe9e826,

title = "Potential SARS-CoV-2 kidney infection and paths to injury",

author = "Luise Hassler and Daniel Batlle",

note = "Funding Information: We acknowledge Jan Wysocki and Juan Carlos Velez for the careful reading of the manuscript and their suggestions before submission. We acknowledge the support of a gift from the Joseph and Bessie Feinberg Foundation, NIH grant 1R21 AI166940-01 (D.B.) and a stipend from the BMEP to L.H. Funding Information: D.B. is co-inventor of patents entitled “Active Low Molecular Weight Variants of Angiotensin Converting Enzyme 2 (ACE2)”, “Active low molecular weight variants of Angiotensin Converting Enzyme 2 (ACE2) for the treatment of diseases and conditions of the eye” and “Soluble ACE2 Variants and Uses therefor”; is founder of Angiotensin Therapeutics Inc.; has received consulting fees from AstraZeneca, Relypsa and Tricida (all unrelated to this work); and has received unrelated support from National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK104785, as well as from a grant from AstraZeneca. L.H. declares no competing interests.",

year = "2022",

month = may,

doi = "10.1038/s41581-022-00551-6",

language = "English (US)",

volume = "18",

pages = "275--276",

journal = "Nature Reviews Nephrology",

issn = "1759-5061",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Potential SARS-CoV-2 kidney infection and paths to injury

AU - Hassler, Luise

AU - Batlle, Daniel

N1 - Funding Information: We acknowledge Jan Wysocki and Juan Carlos Velez for the careful reading of the manuscript and their suggestions before submission. We acknowledge the support of a gift from the Joseph and Bessie Feinberg Foundation, NIH grant 1R21 AI166940-01 (D.B.) and a stipend from the BMEP to L.H. Funding Information: D.B. is co-inventor of patents entitled “Active Low Molecular Weight Variants of Angiotensin Converting Enzyme 2 (ACE2)”, “Active low molecular weight variants of Angiotensin Converting Enzyme 2 (ACE2) for the treatment of diseases and conditions of the eye” and “Soluble ACE2 Variants and Uses therefor”; is founder of Angiotensin Therapeutics Inc.; has received consulting fees from AstraZeneca, Relypsa and Tricida (all unrelated to this work); and has received unrelated support from National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK104785, as well as from a grant from AstraZeneca. L.H. declares no competing interests.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85125759588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125759588&partnerID=8YFLogxK

U2 - 10.1038/s41581-022-00551-6

DO - 10.1038/s41581-022-00551-6

M3 - Comment/debate

C2 - 35190715

AN - SCOPUS:85125759588

SN - 1759-5061

VL - 18

SP - 275

EP - 276

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

IS - 5

ER -

Potential SARS-CoV-2 kidney infection and paths to injury

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this